Cencora, Inc. $COR Shares Purchased by Jennison Associates LLC

Jennison Associates LLC increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 2.5% in the fourth quarter, Holdings Channel reports. The firm owned 174,003 shares of the company’s stock after buying an additional 4,174 shares during the quarter. Jennison Associates LLC’s holdings in Cencora were worth $58,770,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of COR. Oakworth Capital Inc. acquired a new stake in shares of Cencora in the 4th quarter worth $26,000. Archer Investment Corp lifted its stake in shares of Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares during the period. Optima Capital LLC acquired a new stake in shares of Cencora in the 4th quarter worth $31,000. IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the 3rd quarter worth $30,000. Finally, Cloud Capital Management LLC acquired a new stake in shares of Cencora in the 3rd quarter worth $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the subject of several recent analyst reports. Evercore set a $360.00 target price on shares of Cencora in a research note on Wednesday, April 8th. Leerink Partners restated an “outperform” rating on shares of Cencora in a research note on Tuesday, March 17th. Morgan Stanley set a $380.00 target price on shares of Cencora in a research note on Tuesday, March 17th. Bank of America reduced their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research note on Monday, January 5th. Finally, William Blair initiated coverage on shares of Cencora in a research note on Tuesday. They issued a “market perform” rating for the company. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $398.17.

Cencora Stock Down 1.1%

COR stock opened at $307.90 on Friday. The company has a market cap of $59.90 billion, a P/E ratio of 37.01, a P/E/G ratio of 1.45 and a beta of 0.72. Cencora, Inc. has a 52 week low of $271.00 and a 52 week high of $377.54. The company’s 50-day moving average price is $333.36 and its 200 day moving average price is $342.95. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The firm had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.73 earnings per share. On average, research analysts expect that Cencora, Inc. will post 17.56 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Investors of record on Friday, February 13th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.